Quality of life for non-small cell lung cancer patients in the age of immunotherapy
- PMID: 29782567
- PMCID: PMC5943233
- DOI: 10.21037/tlcr.2018.03.10
Quality of life for non-small cell lung cancer patients in the age of immunotherapy
Conflict of interest statement
Conflicts of Interest: Dr. RA Ramirez serves as a speaker for Guardant Health, Merck & Co., Inc., Genentech, Inc., AstraZeneca, and Ipsen Biopharmaceuticals, Inc. He is also a consultant for Biotheranostics, Advanced Accelerator Applications, and Novartis Pharmaceuticals, Corp. The other authors have no conflicts of interest to declare.
Comment on
-
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.Lancet Oncol. 2017 Dec;18(12):1600-1609. doi: 10.1016/S1470-2045(17)30690-3. Epub 2017 Nov 9. Lancet Oncol. 2017. PMID: 29129441 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources